Team:Heidelberg/Parts
From 2010.igem.org
(→miBricks- The Parts Concept) |
|||
Line 92: | Line 92: | ||
</center> | </center> | ||
- | == | + | ==Endogenous Binding Site Patterns== |
<center> | <center> | ||
{| class="wikitable sortable" border="0" style="text-align: left" | {| class="wikitable sortable" border="0" style="text-align: left" |
Revision as of 14:08, 27 October 2010
miBricks- The Parts Concept
The parts we submit refer to the two core aims our project is focusing on: Reaching regulatory control (1) and specificity (2) of gene expression of any gene of interst in any target cell or tissue of choice. Therefor we engineered parts, that adress those two aims on two different regulatory levels. First, we engineered gene therapy vectors based on synthetic adeno associated viruses. On parts level, we provide about 50 plasmids that can be used for creating shuffeled AAV libraries or even rationally designed, recombinant AAV vectors. Those parts, we refer to as virobytes, are designed in a format, that is directly applicable for the Virobytes Assembly protocol we provide. On RNA level we provide the miTuner toolkit consisting of roughly 60 parts enabling gene expression control based on synthetic or cell-specific endogenous microRNAs. This toolkit consits of three main constructs: The pSMB_miMeasure binding site characterization standard and two pSMB_miTuner expression controlling plasmids. Furthermore, it contains 12 basic and 28 intermediate constrution parts, synthetic single microRNA binding sites as well as binding site patterns in BB-2 (RFC 12, Tom Knight) standard. This enables maximum flexibility for applications in many different contexts.
Main Measurement Constructs - Engineered
Synthetic Single Binding Sites
Endogenous Binding Site Patterns
miTunig Kit - Basic Parts
miTuning Kit - Intermediate Parts 1
Tuning Kit - Intermediate Parts 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||